Reaven G M, Swislocki A L, Jeng C Y, Hollenbeck C B, Schwartz K, Chen Y D
Department of Medicine, Stanford University School of Medicine.
Horm Metab Res. 1988 Oct;20(10):633-6. doi: 10.1055/s-2007-1010903.
Measurements of various aspects of glucose, insulin and lipid metabolism were made before and after the administration of enprostil (a synthetic dehydroprostaglandin E2) for one week to ten patients with non-insulin-dependent diabetes mellitus (NIDDM). Both fasting (P less than 0.01) and postprandial (P less than 0.001) plasma glucose concentrations were significantly lower after one week of enprostil, and 24 hour urinary glucose excretion was reduced from (mean +/- SEM) 47 +/- 14 to 25 +/- 9 g/day. There was no change in either fasting or postprandial insulin concentration, but the postprandial GIP response was also significantly reduced (P less than 0.001). In addition, there were significant reductions in postprandial plasma free fatty acid (P less than 0.05) and triglyceride (P less than 0.001) concentrations, associated with a modest fall in fasting plasma triglyceride (P less than 0.05) and cholesterol (P less than 0.07) concentrations when measured after one week of treatment with enprostil. These results raise the possibility that enprostil may be of some benefit in the treatment of patients with non-insulin-dependent diabetes.
对10名非胰岛素依赖型糖尿病（NIDDM）患者给予恩前列素（一种合成的脱氢前列腺素E2）一周前后，进行了葡萄糖、胰岛素和脂质代谢各方面的测量。服用恩前列素一周后，空腹（P<0.01）和餐后（P<0.001）血浆葡萄糖浓度均显著降低，24小时尿糖排泄量从（均值±标准误）47±14克/天降至25±9克/天。空腹或餐后胰岛素浓度均无变化，但餐后GIP反应也显著降低（P<0.001）。此外，服用恩前列素一周后测量发现，餐后血浆游离脂肪酸（P<0.05）和甘油三酯（P<0.001）浓度显著降低，同时空腹血浆甘油三酯（P<0.05）和胆固醇（P<0.07）浓度略有下降。这些结果提示，恩前列素可能对非胰岛素依赖型糖尿病患者的治疗有一定益处。
